HC Wainwright reaffirmed their buy rating on shares of Sanara MedTech (NASDAQ:SMTI – Free Report) in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a $50.00 price objective on the stock.
Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $44.00 price objective on shares of Sanara MedTech in a report on Wednesday.
Read Our Latest Research Report on SMTI
Sanara MedTech Stock Performance
Sanara MedTech (NASDAQ:SMTI – Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.28. The business had revenue of $21.67 million during the quarter. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. During the same quarter last year, the firm earned ($0.13) EPS. As a group, sell-side analysts forecast that Sanara MedTech will post -1.33 earnings per share for the current year.
Institutional Trading of Sanara MedTech
A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in shares of Sanara MedTech by 127.2% during the third quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock worth $123,000 after acquiring an additional 2,272 shares during the period. Geode Capital Management LLC raised its stake in shares of Sanara MedTech by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after buying an additional 3,755 shares in the last quarter. Barclays PLC lifted its holdings in shares of Sanara MedTech by 323.0% in the 3rd quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after buying an additional 4,376 shares during the period. State Street Corp boosted its stake in shares of Sanara MedTech by 9.2% in the third quarter. State Street Corp now owns 58,688 shares of the company’s stock valued at $1,775,000 after buying an additional 4,932 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new position in Sanara MedTech during the fourth quarter worth $898,000. Institutional investors and hedge funds own 8.10% of the company’s stock.
Sanara MedTech Company Profile
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
Further Reading
- Five stocks we like better than Sanara MedTech
- How to Evaluate a Stock Before Buying
- Bloom Energy: Powering the Future With Decentralized Energy
- What is the Dogs of the Dow Strategy? Overview and Examples
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Buy P&G Now, Before It Sets A New All-Time High
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.